Manages hypertension. ANDA 75109, held by Amneal Pharm. Guanfacine Hydrochloride.
As of Nov 16, 2026, ANDA 75109 (Guanfacine Hydrochloride), held by Amneal Pharm, was first approved by FDA on Nov 25, 1998, with 3 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Guanfacine tablets are indicated in the management of hypertension. Guanfacine may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 25, 1998 | Original application | Approved | None posted |
| Guanfacine HydrochlorideEQ 1MG BASE · tablet;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 2MG BASE · tablet;oral | Guanfacine Hydrochloride | Rx |
| Feb 19, 2014 | Supplement 5Manufacturing | Approved | None posted |
| Nov 4, 2002 | Supplement 3Labeling | Approved | None posted |
| Jun 22, 2001 | Supplement 1Manufacturing | Approved | None posted |
| Nov 25, 1998 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters